Objectives-Glial-derived primary brain tumours, gliomas, are among the fastest growing malignancies and present a huge clinical challenge. Research suggests an important, yet poorly understood, role of ion channels in growth control of normal and malignant cells. In this study, we sought to functionally characterize Transient Receptor Potential Canoncial (TRPC) channels in glioma cell proliferation. TRPC channels form non-selective cation channels that have been suggested to represent a Ca 2+ influx pathway impacting cellular growth.
INTRODUCTION
Gliomas are primary brain tumours believed to arise from glial cells or their progenitors. They account for 40% of all central nervous system tumours, but represent 78% of malignant brain tumours (Schwartzbaum et al. 2006) . The vast majority of gliomas are high-grade glioblastoma multiforme, and are characterized by almost unrestrained growth. Consequently, the median survival of patients with glioblastoma multiforme is well under 1 year (Huncharek & Muscat 1998) and, while research has generated abundant information regarding the growth characteristics of these cancers, clinical care remains palliative and the prognosis dismal (Butowski et al. 2006) .
Growth control of cancer cell populations has been studied extensively over the past decades and research has identified a multitude of proteins involved in the process yet transmembrane ion channels were initially among the more surprising protein candidates (Schonherr 2005) . While our understanding of their exact role in the physiology of cell proliferation remains tentative, many ion channel blockers also retard cell population growth, which supports the notion that ion channels are an intrinsic component of the cell cycle. It is, therefore, not surprising that ion channels are pursued as potential targets in the development of new anticancer drugs (Fiske et al. 2006) .
A recent addition to the number of channels implicated in cancers is that of transient receptor potential (TRP) channels, more commonly associated with cellular stress responses (Bodding 2007) . These non-selective cation channels, which under physiological conditions flux Ca 2+ into the cell, are thought to assemble as tetramers, where each subunit consists of six transmembrane domain proteins with overall similarity to voltage-gated potassium channels. TRP channels were originally identified by their homology to the trp mutant found in Drosophila melanogaster that displays a transient voltage potential in response to light, in comparison to wild-type flies. In mammals, the superfamily consists of 28 channels that have been subdivided into seven subfamilies according to their homology (Ramsey et al. 2006) .
The canonical subfamily of TRP channels (TRPC) displays most homology to the original channel found in Drosophila (Wes et al. 1995) and this seven-member channel family has been studied extensively since the mid-1990s using recombinant overexpression models; but their role in native cells remains enigmatic although they have been suggested to represent the longsought pathway for store-operated calcium entry. Evidence for store-operated calcium entry includes studies that show knockdown or silencing of TRPCs in cells, such as in DT-40 B cells and human pulmonary artery endothelial cells, reduces store-operated calcium entry seen on thapsigargin stimulation (Brough et al. 2001) . However, other mechanisms of activation have also been proposed for all the TRPC channels and direct activation by diacylglycerol, without store release, has been demonstrated for TRPC-3, -6 and -7 (Beck et al. 2006) . While TRPC channels may be the store-operated calcium channels in some cell types, their involvement seems to depend on TRPC subunit multimerization and expression of other binding partners such as STIM1 (stromal interaction molecule 1) (Clapham 2003) .
What remains undisputed is the potential of TRPC channels to affect calcium signaling, especially in non-excitable cells, and it is in this vein that these channels may play an important role in cell proliferation. Changes in intracellular calcium are intrinsically associated with cell proliferation (Takuwa et al. 1995) and defined calcium signaling events are necessary for cell cycle progression (Whitaker 2006) . Activation of TRPC channels typically occurs through the activation of phospholipase C and this signaling cascade is the target of a number of G-protein-coupled receptors and receptor tyrosine kinases. An important form of TRPC activation has been shown downstream of the epidermal growth factor receptor (EGFR) (Odell et al. 2005 ) that is the major growth factor receptor in malignant gliomas. Indeed, mutated or amplified EGFR is often observed in malignant gliomas and has been associated with the increased cell proliferation seen in them (Bryant et al. 2004) . In Cos-7 cells, EGFR activation causes phosphorylation of TRPC4 and results in channel insertion into the plasma membrane (Odell et al. 2005) . Additionally, knockdown of TRPC4 in human corneal epithelial cells suppresses epidermal growth factorinduced cell proliferation, again linking proliferation to TRPC channels (Yang et al. 2005) . Moreover, a study in human pulmonary artery myocytes showed higher expression of TRPC-1, while cells were proliferating that was also correlated with increased capacitative Ca 2+ entry (Golovina et al. 2001) .
In light of the potential for TRPC channels to impact calcium dynamics and be impacted on by EGFR signaling, we hypothesized that TRPC channels may have important roles in growth control of human glioma cell populations. Using a combination of molecular, biochemical and biophysical approaches, we demonstrate the expression of at least four TRPC channel proteins in patient biopsies and cell lines derived from patient tumours. These give rise to functional TRPC channels that contribute significantly to the cells' resting conductance. Importantly, chronic inhibition causes growth arrest through inhibition of cytokinesis leading to multinucleate, enlarged cells.
MATERIALS AND METHODS

Cell culture
The majority of experiments were performed using the glioma cell line D54MG (World Health Organization grade IV, glioblastoma multiforme) that was provided as a gift by Dr. D. Bigner (Duke University, Durham, NC, USA). Cells were maintained in Dulbecco's modified Eagle's medium/Ham's F-12 50/50 Mix (DMEM/F12) and were supplemented with 2 mM glutamine (media and glutamine supplied by Media Tech, University of Alabama at Birmingham Media Preparation Facility) and 7% fetal bovine serum (Aleken Biologicals, Texarkana, AR, USA), at 37 °C and 10% CO 2 . For time-lapse imaging, we utilized a stable cell line of D54MG cells transfected with pEGFP-N1 (Clontech, Mountain View, CA, USA). Clones were selected by G148 tolerance, individual cells were sorted by fluorescence-activated cell sorting (FACS) analysis; colonies were generated from single cells.
Drugs and solutions
TRPC inhibitors SKF96365, gadolinium (III) chloride, and 2-aminoethoxydiphenylborane were obtained from Sigma Aldrich (St. Louis, MO, USA). Voltage-gated calcium channel blockers included, ϖ-conotoxin, ϖ-agatoxin, SNX-482, mibefradil (all from Alomone Laboratories Ltd., Jerusalem, Israel), and nimodipine (Calbiochem, San Diego, CA, USA). Bath solution consisted of the following (in mM): 130 NaCl, 5 KCl, 1 CaCl 2 , 10.5 D-glucose, 32.5 HEPES, pH adjusted to 7.4 with NaOH. Pipette solutions contained the following (in mM): 145 KCl, 1 MgCl 2 , 0.2 CaCl 2 , 10 EGTA, 10 HEPES sodium salt, pH adjusted to 7.2 with Tris-base.
Western blotting
For Western blot analysis, dishes of confluent cells were lysed with RIPA (Radioimmunoprecipitation assay) buffer [50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Nondet P-40 (NP-40), 0.5% sodium deoxycholate, 1% sodium dodecyl sulfate] supplemented with 1: 100 protease inhibitor cocktail (Sigma Aldrich) for 30 min. Lysates were then subjected to centrifugation at 12 000 g at 4 °C for 5 min and supernatant protein levels were quantified using the detergent-compatible protein assay kit (Bio-Rad, Hercules, CA, USA). After quantification, 10 μg of protein was aliquoted and 6× Laemmli's sodium dodecyl sulfate sample buffer containing 600 mM β-mercaptoethanol was added at appropriate proportions; samples were then loaded into individual lanes of 10% pre-cast sodium dodecyl sulfate-polyacrylamide gel electrophoresis (Bio-Rad). Protein separation was accomplished by 100 V for ~90 min. Gels were then transferred at 200 mA for 2 h at room temperature on to polyvinylidene fluoride membranes (Millipore, Bedford, MA, USA). Membranes were blocked in blocking buffer consisting of 5% non-fat milk in TBS-T (Tris-buffered saline Tween-20). Primary antibodies against TRPC channel components were diluted in blocking buffer at 1: 500 for 2 h, followed by three washes. The actin antibody was diluted at 1: 2000 for a 1-h incubation. Membranes were incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h and were then washed. They were developed using FemtoWest (Pierce, Rockford, IL, USA) and were imaged on a Kodak imager (Eastman Kodak Company, New Haven, CT, USA). We obtained antibodies from Chemicon (Temecula, CA, USA) (TRPC-6), Alomone Laboratories Ltd. , and Sigma Aldrich (actin).
Immunocytochemistry
D54 cells were seeded on glass coverslips (12 mm round, Macalster Bicknell, New Haven, CT, USA) and, once they reached 70% confluency, were fixed in 4% paraformaldehyde for 15 min then rinsed at room temperature. Cells were permeabilized with phosphate-buffered saline (PBS), 0.3% Triton, and 5% goat serum for 30 min at room temperature and were washed once with PBS and 5% goat serum. Primary TRPC antibodies, 1: 100 dilution in PBS with 1% goat serum, were incubated at 4 °C overnight. The following day, cells were rinsed four times with PBS and were blocked again for 30 min at room temperature, in PBS with 5% goat serum. FITC-conjugated goat antirabbit secondary (1: 500) (Molecular Probes, Eugene, OR, USA) and TRITC-conjugated phallodin (Molecular Probes) 1: 500 in PBS and 5% goat serum, were incubated on cells in the dark for 1 h at room temperature. Cells were then washed once with PBS, incubated briefly with 4′,6-diamidino-2-phenylindole (DAPI) diluted 1: 2000 in PBS, and were washed twice more with PBS. Coverslips were then mounted on glass slides with Gel Mount aqueous mounting medium (Sigma Aldrich).
Electrophysiology
Recordings of whole-cell currents were made using an Axopatch 200A amplifier (Axon Instruments, Foster City, CA, USA) following standard recording techniques (Hamill et al. 1981) . Patch pipettes were made with thin-walled borosilicate glass [World Precision Instruments (TW150F-4), Sarasota, FL, USA] using an upright puller [Narishige Instruments (PP-830), Tokyo, Japan], and typically had resistances of 3-5 MΩ. Current recordings were digitized online at 10 kHz and low-pass filtered at 2 kHz using a Digidata 1322 A (Axon Instruments). pClamp 8.2 (Axon Instruments) was used to acquire and store data. Series resistance (R S ) was compensated to 80% above 10 MΩ were omitted. D54MG to reduce voltage errors and cells with a compensated RS cells cultured on glass coverslips for 2-4 days were used in all experiments. Standard bath solution was continuously exchanged at a rate of ~1 mL/min as were bath solutions containing inhibitors used to block specific channels.
Proliferation assays
For SKF96365 proliferation assays, cells were plated on six-well plates at a density of ~5 × 10 4 . On day zero, to normalize cell number, a well was collected and cell number determined using a Coulter Counter Multisizer 3 (Beckman Coulter, Miami, FL, USA). Remaining wells were treated with 25 μM SKF96365 in culture media or cells were allowed to grow in the absence of drugs. Daily, samples of both control and treated cells were collected and counted using a Coulter Counter Multisizer 3 (Beckman Coulter).
For proliferation assays conducted with voltage-gated calcium channel (VGCC) inhibitors, or 2-aminoethoxydiphenylborane, cells were plated at a density of 1 × 10 4 on 12-well plates to minimize amounts of VGCC inhibitors needed. Because of the low starting number of cells, daily counts were conducted using a hemacytometer. VGCC inhibitors used included 1 μM nimodipine, 1 μM ϖ-conotoxin, 100 nM ϖ-agatoxin, 25 nM SNX-482, and 5 μM mibefradil that inhibited L-type, N-type, P/Q-type, R-type and T-type calcium channels, respectively. Solutions used contained either no drug, the entire VGCC cocktail, VGCC cocktail and 25 μM SKF96365, or 25 μM SKF96365. Cell morphology changes apparent in the proliferation assay only occurred if SKF96365 was present.
Live/dead cells D54 cells were plated onto #1 German borosilicate eight-well chamber slides (Nunc, Rochester, NY, USA) and were cultured for 4 days. After 1 day in culture, two wells were treated with 25 μM SKF96365 and an additional two wells of cells were treated with SKF96365 each consecutive day until the 4 days passed. This resulted in cells treated for 0, 1, 2 and 3 days with SKF96365; the Live/Dead viabilitiy/cytotoxicity kit for mammalian cells (Molecular Probes) was used to assay cell death. Following manufacturer's instructions, cells were gently washed with PBS then were exposed to 4 μM ethidium homodimer-1 and 2 μM calcein acetoxymethyl (AM) in PBS for 30 min. After mounting each coverslip, pictures were taken of the cells randomly throughout the wells and the percentage of live cells was determined by dividing the number of calcein-AM-positive cells by the total number of cells (calcein-AM-positive cells and ethidium-positive cells). Four to five total fields of view were counted per treatment and the experiment was repeated in triplicate.
Cell volume measurements
Cell volumes were measured by electronic sizing with a Coulter Counter Multisizer 3 (Beckman Coulter) as previously described (Parkerson & Sontheimer 2003) . Cell volume is measured by voltage step created as change in resistance that occurs when a cell displaces its volume in electrolyte solution as it passes through a small aperture of 100 μM To prepare for volume measurements, cells were collected by trituration, and then the suspension was pelleted by centrifugation. The pellet was re-suspended in 75 mL of bath solution and volume measurements were taken of an average of 10 000-20 000 cells, after they had equilibrated to room temperature bath solution.
Cell cycle analysis D54MG cells were plated on 100 mm dishes (Corning Inc., Corning, NY, USA) and were treated for either 0, 1, 2 or 3 days with 25 μM SKF96365 or no drugs. Beginning 24 h after SKF96365 treatment, cells were trypsinized, harvested and re-suspended in 0.5 mL sterile PBS. Cell suspensions were then transferred to 2 mL of 95% ethanol by slowly pipetting, while vortexing, to mix thoroughly. Samples were stored at −20 °C and this process was repeated every day for the duration of the experiments. After collection, samples were re-suspended in sterile PBS and were allowed to re-hydrate for 30 min at room temperature. Cells were washed three times with PBS and then were treated with ribonuclease (RNase; 100 μg/mL in PBS) for 15 min. Propidium iodide (50 μg/mL in PBS) was added and cells were allowed to incubate for an additional 30 min. Using FACS, DNA content was measured by exciting propidium iodide at 488 nm and measuring the emission at 580 nm. ModFit (Verity Software House, Topsham, ME, USA) was used to analyse cell cycle distribution.
Timelapse imaging
D54MG-GFP (green fluorescent protein) cells were plated on #1 German borosilicate twowell chamber slides (Nunc) to reach ~50% confluency after 24 h. To stain nuclei, 100 ng/mL Hoechst 33342 (Sigma Aldrich) was loaded for the cells for 20 min, they were rinsed with media once, and were allowed to equilibrate in the incubator for 30 min prior to drug treatment. Immediately, prior to beginning the time lapse experiment, cells were treated either with 25 μM SKF96365 or received no drug treatment and were placed on the microscope to equilibrate to temperature and humidity.
Time lapse images were acquired with an Axiocam MRm camera mounted on an Axiovert 200M inverted microscope equipped with a motorized stage and filter cube turret (Carl Zeiss, Thornwood, NJ, USA). The microscope was enclosed in a temperature and controlled CO 2 humidified incubator maintained at 37 °C and 5% CO 2 , 95% ambient air. Chamber slides were placed on the microscope for at least 20 min before the beginning of the experiment to allow for temperature equilibration. Wide field fluorescence was generated from a metal halide Xcite 120 light source (EXFO Photonics Solutions Inc., Mississauga, Ontario, Canada) and was reflected through a FITC (excitation at 480 ± 15 nm, emission at 535 ± 20 nm) filter cube for GFP fluorescence or a DAPI (excitation at 350 ± 25 nm, emission at 460 ± 25 nm) filter cube (Chroma Technologies, Burlington, VT, USA) for Hoechst 33342 fluorescence. Neutral density filters were used to attenuate light and to prevent phototoxicity. Time lapse experiments were conducted with a 20× Fluar air objective. Phase contrast and fluorescent images were obtained at defined intervals for 48 h, and four fields per treatment condition were imaged at each time point. Time lapse experiments were repeated in triplicate.
Data analysis
Results were analysed using Origin (version 6.0, Microcal Software Inc., Northampton, MA, USA). Significance was determined by one-way ANOVA or Student's t-tests, as appropriate, because all data showed normal distribution. All data reported are mean ± SEM and * denotes P < 0.05 unless otherwise stated.
RESULTS
Western blot analysis and immunocytochemistry demonstrating TRPC protein expression in glioma cell lines and patient biopsies
In a first attempt to identify the complement of TRPC channels expressed in gliomas, we examined protein expression using Western blot analysis with subtype-specific antibodies to TRPC channels. Fortunately, antibodies are now available for five of the seven human TRPC channels and these include five of the six channels for which we detected TRPC mRNA transcripts in gliomas (mRNA data not shown). We directly compared protein expression for a panel of glioma cell lines with results shown in Fig. 1a . Cell lines used included a grade III glioma (STTG1), grade IV gliomas (D54, D65, U87, U251), and one cell line derived directly from a patient with a grade IV glioblastoma (GBM62). As internal control, we used human fetal astrocytes as mRNA transcripts for all TRPC channels, except TRPC-2, have been shown in astrocytes (Pizzo et al. 2001 ). In addition, we probed tissue lysates acutely established from two glioma biopsies (grade IV, glioblastoma) and two non-malignant human brain samples (Fig. 1b) . While we saw some differences in expression levels, we found some notable commonalities. For example, all cell lines and tissue lysates showed prominent expression of TRPC-5. All malignant tissues and cell lines additionally expressed TRPC-1 and all but one (STTG1) expressed TRPC-3. Weakest and most variable expression was observed for TRPC-4 and we saw TRPC-4 and TRPC-5 express two bands in our cell lines that we believe are glycosylated or unglycosylated subunits. Our human fetal astrocyte control, in agreement with past reports, expressed all TRPC channels albeit weak TRPC-1 expression.
To characterize TRPC expression in glioma cells, we focused on D54MG cells in the biochemical and immunocytochemistry studies below. D54MG cells expressed four TRPC channels that were detected by Western blotting. Representative examples shown in Fig. 2 show staining for TRPC-1, -3 and -4 that were widespread over the cell surface, whereas TRPC-5 was somewhat enhanced in perinuclear localities. As control, we excluded primary antibodies from staining and observed no FITC labelling in these cohorts, indicating no secondary antibody background binding (not shown). In addition, as indicated by the Western blot data, we noted no TRPC-6 staining.
Currents mediated by glioma TRPC channels
We next wanted to assess whether any of the expressed TRPC proteins would assemble into functional channels. To date, the majority of studies on TRPCs have used recombinant systems and expressed these proteins as either homo-or heteromers. We employed whole-cell patchclamp electrophysiology in conjunction with two drugs known to inhibit TRPC channels, in recombinant systems. Specifically, SKF96365 and gadolinium chloride have been widely reported in the literature to block TRPC channels (Gustafsson et al. 2005) . Although both compounds also inhibit VGCC to some extent, we confirmed by Western blotting (unpublished results) that glioma cells used in our studies do not express VGCC channels targeted by these two drugs. The most prominent current in gliomas is mediated by large conductance K + channels, referred to as BK channels (Ransom & Sontheimer 2001) , giving rise to outwards K + currents that are highly sensitive to paxilline and iberiotoxin (Basrai et al. 2002) . These, however, require large membrane depolarization or high intracellular [Ca 2+ ] for their activation (Ransom & Sontheimer 2001) . Representative current recordings are shown in Fig. 3 from D54MG cells before and after application of paxilline, to inhibit BK currents. We next applied SKF96365 to isolate the TRPC-mediated SKF-sensitive current components, attributable to TRPC channels, by subtracting currents in the presence of SKF + paxilline from those with paxilline alone (Fig. 3a) . Voltage step protocols utilized throughout held cells at −40 mV and stepped in 10 mV increments from −80 mV to 140 mV for 100 ms. To compare before and after drug application, inhibitor was allowed to wash over the cells for 2 min for complete inhibition. Similar experiments were repeated for 12 cells, for each inhibitor, and mean currents normalized to cell capacitance (current density) were plotted, as a function of the applied voltage (IV) curves in Fig. 3(b,c) . Isolated currents sensitive to TRPC channel inhibitors, 25 μM SKF96365 or 10 μM GdCl 3 , were small and linear, and did not display any voltage dependence. Average current densities were 6 pA/pF at +140 mV and reversed at ~25 mV and 10 mV for SKF96365 and GdCl 3 , respectively (Fig. 3b ). For comparison, we plotted IVcurves for paxilline-sensitive currents indicated in Fig. 3c , which showed strong outwards rectification and much larger conductance. While single-channel expression studies have reported varying selectivity and conductance between the seven homomeric channels (Nilius & Voets 2005) , small, linear currents attributed to TRPC channels within native cells have been reported that are similar to currents we observed in D54MG cells (Wang & Poo 2005) .
Additionally, in order to ascertain that these two inhibitors blocked the same currents, we first applied 10 μM Gdcl 3 and then added GdCl 3 + 25 μM SKF96365 (n = 5) and subtracted both currents to isolate current sensitive to each inhibitor (supplementary Fig. 1a) . We did not observe any notable additional current for voltages up to +50 mV. Furthermore, we were interested in investigating whether the inhibitors were acutely reversible. To this end, we obtained voltage steps before drug addition, applied the drug for 2 min, and again obtained voltage steps after we had washed off all inhibitor for 3 min. We then subtracted both traces to isolate any residual current that was resistant to washout. As shown in supplemental data Fig. 1b, SKF96365 (n = 4) washed out completely, whereas GdCl 3 did not (n = 5). For this reason, we used GdCl 3 only sparingly, further.
We noticed that as we applied TRPC inhibitor to cells, input resistance measured at the holding potential of −40 mV (i.e. close to the cells' resting potential) increased by an average of 14.5 ± 3.95 MΩ (SKF96365 n = 6, data not shown), indicating that channels that were open at rest were blocked by SKF96365. In contrast, application of paxilline, while blocking outwards currents in response to voltage steps, did not show any change in input resistance at −40 mV under identical recording conditions, thus suggesting that BK channels did not contribute to resting membrane conductance. To further examine a possible contribution of TRPC channels to resting conductance, and hence resting membrane potential, we performed current clamp experiments, during which the two TRPC channel inhibitors were applied and representative traces are shown in Fig. 4a,b . Application of either SKF96365 or GdCl 3 each caused transient hyperpolarization from the resting potential, shown in Fig. 4 , for two representative cells, followed by sustained depolarization of the membrane potential. These changes were observed in all 29 cells examined and average changes in membrane potential for hyperpolarization were −9.07 ± 1.49 mV (n = 29) for SKF96365 and −10.25 ± 2.17 mV (n = 28) for GdCl 3 (Fig. 4c) . TRPC channels have been demonstrated to effect membrane potential response in other cell types, including hippocampal neurones (Amaral & Pozzo-Miller 2007) and dorsal raphe serotonin neurones (Aman et al. 2007) .
Having demonstrated that these two inhibitors block currents similar to those ascribed to TRPC channels and that they indeed block currents contributing to resting conductance of these cells, we next sought to examine potential involvement of these channels in the biology of glioma cells. TRPC channels have been implicated in growth control in human corneal cell populations (Yang et al. 2005) and, because gliomas present with aberrant growth, studying TRPC channel involvement in growth control was a logical next step.
Chronic SKF96365 treatment inhibits proliferation
To ascertain a possible involvement of TRPC channels in cell proliferation, we compared D54MG cells that were treated with 25 μM SKF96365 to untreated control sister cultures and determined the increase in cell number over a 4-day period using a Coulter Counter. Mean data from three experiments are shown in Fig. 5a and indicate the relative increase in cell numbers normalized to the starting cell number on day zero. Untreated control cell number increased over 30-fold over a 4-day period. The cell cycle length of D54MG cells is 22 h (Habela & Sontheimer 2007) and, hence, the vast majority of cells must have contributed to the exponential growth. In contrast, chronic treatment with SKF96365 dramatically attenuated cell proliferation. This difference was significant by 2 days after treatment, from control-untreated cells (Fig. 5a ). Following 4 days of SKF96365 treatment, treated cells only attained a 1.29 ± 0.16 (n = 3) fold increase in overall cell number, which is essentially no growth at all. Because SKF96365 can also inhibit VGCCs in certain cell types, we carried out the same experiments in the presence of a VGCC inhibitor cocktail targeting essentially all known VGCCs. This cocktail of inhibitors included, nimodipine, ϖ-conotoxin, ϖ-agatoxin, SNX-482 and mibefradil, to block L, N, P/Q, R and T-type voltage-gated calcium channels, respectively. As illustrated in Fig. 5b , specific inhibition of VGCCs had no effect on glioma cell proliferation indicating that proliferation arrest with SKF96365 was unrelated to VGCCs and more likely due to an inhibition of TRPC channels. Over 3 days, cells with VGCC inhibition alone did not differ in their proliferation from drugless controls, with a 9.0 ± 3.9 versus 9.8 ± 5.0 fold increase, respectively (n = 3). In comparison, addition of SKF96365 to the cocktail and SKF96365 alone allowed cells to proliferate to only 1.56 ± 0.63 and 1.45 ± 0.41 fold increases, respectively. SKF96365-induced decrease in cell proliferation was not linked to cell death. There was no appreciable cell death, as determined by the relative number of viable cells using the Live/ Dead assay, until 3 days after treatment. Although 3 days of SKF96365 treatment did result in significantly more dead cells than in controls, 90.5 ± 0.9% of cells were still viable (Fig. 5c) . The other treatments resulted in 99.6 ± 0.4%, 99.1 ± 0.7% and 98 ± 1.1% for no treatment, 1 day of treatment, and 2 days of treatment with SKF96365, respectively (n = 3). Because the Live/Dead assay used captures apoptotic and necrotic cell death, and because only a small proportion of the cells were dying even at 3 days of treatment, we concluded the dramatic cell arrest in cell proliferation could not be due to increased cell death over the entire time period.
We further investigated growth inhibitory effects of TRPC inhibition by analysing cell cycle progression of glioma cells using FACS analysis, to directly compare cells treated with 25 μM SKF96365 over 3 days to untreated sister cultures. Because cells did not die, we expected to find phase; most of the cells arrested in G 0 phase; however, we were intrigued to find that the vast majority of cells accumulated in G 2 + M phase phase of the cell cycle over 3 days. Representative data G 2 (n = 3) are shown in Fig. 6a where, after 24 h, approximately 85% of the SKF96365-treated while control cells had only 14% of cells in G 2 + M, with the majority being in G 1 phase. For the following 2 days of treatment, percentages of cells in G 2 + M for each condition remained approximately stable. These data suggest unusual cell cycle arrest in the G 2 + M phase of the cell cycle.
As the SKF96365 cell proliferation assays were performed by counting cell populations on a Coulter Counter/Cell Sizer, we were concurrently able to record mean cell sizes/volumes of the cell samples counted. Quite unexpectedly, we observed that the D54MG cells treated with 25 μM SKF96365 showed a dramatic and steady increase in mean cell volume/size over the 3-day period investigated and more than doubled their volume from the starting volume (Fig.  6b) .
Inhibition of TRPCs with SKF96365 inhibits cytokinesis
The experiments described above prompted us to investigate glioma cell population growth in the presence of SKF96365 by time-lapse video microscopy, and representative data are shown in Fig. 7 . For these experiments, to visualize cells under time-lapse microcopy, we used D54MG cells stably transfected with GFP and labelled with Hoechst 33342, a live cell compatible nuclear dye. We followed four fields of cells in both conditions for 48 h (n = 3). Representative fields are shown at 48 h of treatment from both control and SKF96365-treated D54MG-GFP cells (Fig. 7a, supplemental video 1) . We observed that, while control cells proliferated and increased their cell number on average 3.91 ± 0.56 fold, SKF96365 treated cells did not. The average number of treated cells did not significantly change, only a 1.11 ± 0 0.18 fold increase, although cells continued to migrate in and out of the field of view (Fig.  7b, supplemental video 2) . However, as suggested by the cell volume measurements described in Fig. 6e , we observed that treated cells grew much larger in cell size (Fig. 7a ) and, importantly, were multinucleate. Hoechst staining of their DNA allowed us to observe cell nuclei throughout the experiment and a significant proportion of the cells treated with 25 μM SKF96365 became multinucleate. After 48 h, treated cells had, on average, 43.2 ± 12.4% of cells multinucleate in comparison to control at 1.53 ± 0.69% multinucleation (Fig. 7c) . When we carried the timelapse photography out further, we observed the same trend of decreased proliferation and increased multinucleation in SKF96365-treated D54MG-GFP cells (data not shown). As a qualitative measure, in Fig. 8 , we show individual D54MG-GFP cells going through a mitotic event. In Fig. 8a , an untreated cell starts with processes extended, rounds up to undergo mitosis, begins to divide and becomes two cells (positions 1-4). For this cell in particular, mitosis was complete within a half hour. Conversely, a SKF96365-treated cell (Fig. 8b, supplemental video 3) again started with processes extended, rounded up and remained rounded for several hours; it appeared to try to separate into two cells, but ended up larger and multinucleate (positions 1-4). Taken together, these data suggest that SKF96365-treated cells grow in size and become multinucleate, leading us to conclude that inhibition of TRPC channels by SKF96365 impaired the D54MG cells' ability to undergo cytokinesis.
Chronic SKF96365 treatment impacts on TRPC currents
The above experiments beg the question as to whether long-term treatment with SKF96365 chronically reduced whole-cell TRPC currents in these cells. We, therefore, performed parallel experiments in which sister cells that underwent time-lapse studies were also recorded by whole-cell patch clamp, both receiving identical treatment with SKF96365. As we recorded from D54MG cells chronically treated, we measured whole-cell capacitance as a direct measure of cell size and again noted an increase in cell size from 49.3 ± 4.3 pF (n = 4) in untreated cells to 79.3 ± 7.9 pF (n = 9) and 94.5 ± 3.6 pF (n = 4) over 2 and 3 days of treatment, respectively (Fig. 9a) . These data correlated very well with the volume increase determined by our Coulter Counter and time-lapse observations. As shown in Fig. 9b , after 3 days of treatment with SKF96365, mean data (n = 4) demonstrate that whole-cell currents had no SKF-sensitive current. Meanwhile, untreated sister cells (n = 4) still exhibited SKF-sensitive currents as described at the outset of the study (Fig. 9b) . Because we have shown that SKF96365 effects are reversible, these data indicate that chronic treatment with SKF96365 abolishes TRPC channel function.
To further investigate how chronic treatment with SKF96365 impacts TRPC channels, we examined protein expression by Western blotting and immunocytochemistry. After treating D54MG cells with 25 μM SKF96365 for 0, 1, 2 or 3 days, lysates were collected and blots were probed with antibodies to TRPC channel components and no noticeable decreases were observed in protein expression in any of the TRPC channels probed (Fig. 9c) . However, by immunocytochemistry (Fig. 10) , we observed that TRPC channels appeared to localize more to perinuclear regions of the cells in comparison to non-treated controls when the cytoskeleton of treated cells was costained with phallodin. We hypothesize that TRPC channels are removed from the plasma membrane on chronic treatment with SKF96365.
2-Aminoethoxydiphenylborane inhibits similar TRPC currents and impairs cell proliferation
Because SKF96365 is a non-specific inhibitor of TRPC channels, we sought to further validate that TRPC channel inhibition specifically leads to a deficit in cytokinesis and at cell proliferation. In this vein, we used a further non-specific TRPC inhibitor, 2-aminoethoxydiphenylborane (2-APB), to repeat key experiments from this study (Sekaran et al. 2007) . 2-APB is also known to inhibit inositol triphosphate receptors (IP3R), but not to inhibit VGCCs as does SKF96365. Conversely, SKF96365 is not reported to block IP3Rs and, thus, the overlap in inhibition activity for these two drugs is restricted to TRPC channels. First, we sought to determine whether 2-APB would inhibit similar currents as SKF96365 in D54MG cells, and we observed by voltage step averages (n = 5), that 100 μM 2-APB inhibits similar currents as SKF96365 (Fig. 11a) . The currents are, like SKF96365-sensitive currents, small and linear with a reversal potential of −25 mV and reach a maximum current of 8 pA/pF. After observing similar current inhibition, we next sought to determine whether chronic treatment to inhibit TRPC channels with 100 μM 2-APB would impact cell proliferation. Mean data from three separate proliferation assays are shown in Fig. 11b , and we observed that 100 μM 2-APB inhibited proliferation to the same extent as 25 μM SKF96365 and was significantly (P < 0.05) lower than control cells starting after only 1 day of treatment. After 3 days treatment, we saw control cells reach 13.5 ± 4.4 fold their starting cell number while cells treated with TRPC inhibitors were unable to increase their cell numbers past 1.4 ± 1, for 100 μM 2-APB or 0.9 ± 0.2, for 25 μM SKF96365.
We next sought to determine whether chronic treatment of D54MG cells with 2-APB would impact TRPC currents to the same extent as SKF96365 treatment. As shown in Fig. 11c after 3 days of treatment with 2-APB, the SKF-sensitive current (n = 4) from the whole-cell currents is no longer apparent. Taken together, treatment with 100 μM 2-APB mimicked the effects that we observed with SKF96365 and hence substantiates the notion that the effects of both inhibitors were mediated by TRPC channel inhibition. This also indicates that TRPC channel inhibition caused the deficit in cytokinesis that we observed with SKF96365 and 2-APB.
DISCUSSION
Over the past decade, numerous articles have been published that implicate ion channels in the growth control of cancer cell populations (Schonherr 2005) . Some have even added cancer to the list of diseases presenting with an ion channel defect or phenotype, commonly referred to as 'channelopathies' (Fiske et al. 2006) . A recent addition to the channels implicated in cancers is that of the TRP channels, more commonly associated with cell stress responses (Bodding 2007) . Lack of knowledge regarding TRPC expression and function in gliomas motivated this investigation that revealed the expression of at least four of the TRPC channel subtypes across many glioma cell lines and patient biopsies. Most surprising, however, was the finding that pharmacological inhibition of TRPC channels disrupts glioma cytokinesis leading to bizarre and greatly enlarged multinucleated cells. Such multinucleate and enlarged cells are a defining histopathological feature of high-grade gliomas known as glioblastoma multiforme (Kleihues et al. 1995) therefore suggesting that a defect in TRPC channel function may contribute to the cell morphology observed in these tumours.
The most prominent TRPC channels found in our survey were TRPC-1, -3, -4 and -5 all of which we also found in human fetal astrocytes. Universal lack of expression of TRPC-2 (mRNA transcript data not shown) was not surprising as it is considered a pseudogene in humans. TRPC-6, on the other hand, while present at low levels in some gliomas was most highly expressed in human fetal astrocytes, consistent with previously published reports on astrocytes (Pizzo et al. 2001) . TRPC channels are thought to be heteromultimeric channels composed of different TRPC proteins (Hofmann et al. 2002) . While our studies identify the possible complement of proteins available for heteromerization, they cannot identify the subunit composition or even rule out the presence of homomeric channels composed of one type of TRPC protein. The vast majority of biophysical data for TRPC channels comes from expression of single TRPC genes, hence, are characteristic of homomeric channels. Native studies have shown typically small linear currents similar to the ones we have seen (Wang & Poo 2005) .
While this search for TRPC channels involved a number of widely used cell lines and patient biopsies we chose one cell line in particular, D54MG, for our biophysical studies. D54MG glioma cells are derived from a high-grade (WHO grade IV) glioma and have been widely used and extensively described in the literature (Ghahary et al. 2002) and in many of our previous studies (Ullrich et al. 1998) . In agreement with several of our other glioma cell lines, they did not express TRPC-6 mRNA or protein. In this cell line, we were able to isolate currents mediated by TRPC channels using three common TRPC inhibitors, GdCl 3 , SKF96365 and 2-APB. None of these drugs are entirely specific; however, all three blocked similar currents and we ruled out possible effects of SKF96365 on VGCCs. First, glioma cells lack VGCC expression as determined by Western blotting (data not shown) and, second, a cocktail targeting all known VGCCs was without effect on cell population growth.
Isolated TRPC-mediated currents were of small amplitude and lacked any apparent voltagedependence. Yet, they were active at all times even in unstimulated cells. Furthermore, blockade of these currents caused hyperpolarization, followed by depolarization of the membrane potential, suggesting that these channels contribute to the cells' resting conductance. This was the impetus to evaluate the possibility that these channels contribute to cellular physiology. Of course, the most important and detrimental biological feature of glioma cells is their unrestrained growth. Prior studies have implicated ion channels in the control of cell proliferation and tumour growth (Schonherr 2005) .
To assess whether inhibition of TRPC channels affects glioma growth, we used SKF96365 as a chronic inhibitor of TRPC channels, applying the drug continuously for up to 4 days. Strikingly, cell proliferation came to a rapid and near complete halt in presence of the drug, without killing cells; FACS analysis revealed arrest at the G 2 + M phase of the cell cycle. This was surprising because translation cannot occur while cells are undergoing mitosis and most cell cycle inhibitors can not arrest a cell in G 2 + M without inducing cell death (Stark & Taylor 2006) . We were also puzzled to find that the cells survived, because arrest that prohibits cells from completing mitosis usually results in apoptosis, a type of cell death sometimes referred to as mitotic catastrophe (Castedo et al. 2004) . Concurrently, we realized that the D54MG cells continued to grow in size and volume and we used time-lapse microscopy to follow individual cells through the cell cycle more closely. After observing stably transfected D54MG-GFP cells loaded with Hoechst 33342, which stains nuclear DNA in live cells, we were able to conclusively show defects in cytokinesis whereby cells underwent incomplete divisions ending up enlarged and with multiple bizarre nuclei.
Cytokinesis, which begins at the onset of anaphase, is the division of remaining cytoplasmic substances in the cell, aside from the nuclear events of mitosis. It is typically described with two key components being the central spindle and the contractile ring. The central spindle helps to divide cellular contents into the two lobes while the contractile ring, consisting of actin, myosin and other proteins, pinches off the membrane until there are two equal daughter cells (Eggert et al. 2006) . While not separate from mitosis, the nuclear events of mitosis can be completed without completion of cytokinesis. Without cytokinesis, the resulting multinucleate cells can extrude a nucleus, rectify cytokinesis by extra cleavage in the following mitotic cycle, undergo programmed cell death, or remain multinucleate (Glotzer 2005) . The D54MG glioma cells are obviously able to tolerate multiple nuclei and survive well as multinucleate cells.
As a whole, cytokinesis is less well understood than other aspects of the cell cycle, but one key player in contractile ring formation is RhoA guanosine triphosphatase (GTPase), which is important for actin nucleation and myosin activation (Bement et al. 2006) . Recently, reports have indicated an association between TRPC-1 and RhoA (Mehta et al. 2003) and, independently, TRPC-6 and RhoA in certain cell types (Singh et al. 2007) . While direct SKF96365 inhibition of RhoA cannot be specifically ruled out in this study, it remains intriguing to suggest that calcium influx via TRPC channels may be essential for activation of cytokinesis in this context and, hence, the inhibition of localized Ca 2+ signal may disrupt complete cytokinesis. Indeed, in primary mouse astrocytes, TRPC proteins are organized around the endoplasmic reticulum and may contribute in localized signaling (Golovina 2005) . Additionally, a study in frog oocytes has recently implicated TRPC-1 as a mechanical sensor that may keep track of the volume of a cell (Maroto et al. 2005) . The cell cycle and cellular volume in glioma cells have been shown to be intricately linked so that cells that have difficulty keeping track of their cell size would likely have difficulty completing their cell cycle (Habela & Sontheimer 2007) .
Clearly, further studies are needed to examine interdependence of cytokinesis with TRPC channel function. However, the findings presented here are exciting as they suggest that TRPC channels are a possible target for the development of desperately needed drugs to interfere with the relentless growth of gliomas. Because glioma cells rely on the ability to adjust their cell volume as they invade the normal brain, one would expect that larger, multinucleate cells would be compromised in their ability to diffusely invade throughout the narrow extracellular brain spaces. This, in turn, may make them more amendable to surgical removal or focal radiation treatment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material. To better visualize the subcellular distribution of TRPC protein in D54MG cells, we utilized rhodamine-conjugated phalloidin (red), to stain the F-actin cytoskeleton and DAPI to stain the cell nuclei (blue). FITC-conjugated secondaries visualize TRPC protein expression (green). We observed broad expression of TRPC-1, -3 and -4 on all aspects of the cells whereas TRPC-5 was slightly more perinuclear. No staining was observed for TRPC-6. Scale bar (top right panel) is representative of 20 μM for all fields of view. Top left panel shows control currents from D54 cells, currents after a BK-specific inhibitor (2 μM paxilline), and currents after a TRPC inhibitor, 25 μM SKF96365. The SKF-sensitive current represents a point-by-point subtraction of currents in the presence and absence of the respective inhibitor. This isolated the TRPC currents as small currents that lack voltage-dependence. (b) Mean cumulative data from 12 cells for each condition were plotted in which currents were normalized to whole-cell capacitance to yield normalized current density plots for 25 μM SKF96365-sensitve and 10 μM GdCl 3 -sensitive currents. (c) Representative data comparing the isolated paxilline-sensitive current mediated by BK channels in comparison to the SKFsensitive currents mediated by TRPC. Paxilline-sensitive current exhibits strong outwards rectification and currents are of much larger amplitude, while the SKF-sensitive current is small and linear more characteristic of a non-selective cation channel like TRPC channels. (a) Using a Coulter Counter, sister cultures were examined that were either treated or untreated with 25 μM SKF96365. Cell counts were normalized to the starting cell numbers that was identical for each condition and mean values from three experiments were plotted. Over a 4-day period, untreated D54MG cells showed greater than 30-fold increase in cell number (30.9 ± 5.5, n = 3) while SKF-treated cells barely increased in number (1.29 ± 0.16, n = 3). The data are plotted as mean ± SEM and the difference between control and SKF-treated cells was significant days 2-4 (P < 0.05) of the treatment. (b) To rule out non-specific effects of SKF96365 acting via blockade of Ca 2+ channels, we used a cocktail of VGCC inhibitors in conjunction with SKF. The cocktail consisted of 1 μM nimodipine, 1 μM ϖ-conotoxin, 100 nM ϖ-agatoxin, 25 nM SNX-482, and 5 μM mibefradil to block L-type, N-type, P/Q-type, Rtype and T-type calcium channels, respectively. D54 cells treated with just the VGCC inhibitor cocktail showed identical growth as untreated control sister cultures over 3-day period (9.0 ± (a) Mean capacitance data demonstrates that D54MG chronically treated with 25 μM SKF96365, over 2 or 3 days, are larger than untreated controls. Untreated cells were 49.3 ± 4.3 pF (n = 4) while cells treated with SKF96365 over 2 or 3 days were 79.3 ± 7.9 pF (n = 9) and 94.5 ± 3.6 pF (n = 4), respectively. Both treatment conditions were significantly different from control (P < 0.05, Student's t-tests). Immunocytochemistry using antibodies to TRPC channels found in D54MG cells on cells treated with SKF96365 for 3 days. D54MG cells that were not treated are shown as a merged image in the right panel as a comparison. The TRPC channels were stained with a FITCconjugated secondary and, notably, appear more perinuclear in localization than the no drug controls. In the merged images, TRITC-conjugated phallodin outlines the border of the cells and DAPI was used to stain the nuclei. TRPC-1 and -3 are most notably different. Scale bars are representative of 20 μM. (a) Mean cumulative data from five cells were plotted for the 2-APB-sensitive current in which currents were normalized to whole-cell capacitance to yield normalized current density before and after application of the TRPC inhibitor, 100 μM 2-APB, for the 2-APB-sensitive current. (b) Proliferation assays (n = 3) demonstrate that inhibition of TRPC channels using 100 μM 2-APB mimics the effects of 25 μM SKF96365 inhibition. Over a 3-day period, control cells reached 13.5 ± 4.4 fold their starting cell number while 2-APB or SKF96365 treated cells reached only 1.4 ± 1 and 0.9 ± 0.2 times their starting cell number. Data is representative of mean ± SEM and became significant (P < 0.05, one way anova) after 1 day of treatment. (c) Chronic treatment with 100 μM 2-APB impairs TRPC channel function as demonstrated by the lack of SKF-sensitive current in chronically treated cells that is similar to chronic treatment with SKF96365 (n = 4). Untreated cells still exhibited SKF-sensitive currents (n = 4).
